HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology (NASDAQ:CRDF) had its price target upped by investment analysts at HC Wainwright from $13.00 to $17.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 318.72% from the stock’s current price.

Separately, Piper Sandler raised their price objective on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday, December 13th.

Cardiff Oncology Trading Down 9.0 %

Shares of NASDAQ CRDF opened at $4.06 on Friday. Cardiff Oncology has a 1 year low of $1.74 and a 1 year high of $6.42. The firm’s 50-day moving average is $4.06 and its 200-day moving average is $3.22. The firm has a market capitalization of $207.60 million, a PE ratio of -4.32 and a beta of 1.77.

Insider Buying and Selling at Cardiff Oncology

In other news, Director Gary W. Pace bought 350,115 shares of the stock in a transaction on Wednesday, December 11th. The stock was purchased at an average price of $2.60 per share, with a total value of $910,299.00. Following the completion of the purchase, the director now owns 1,047,876 shares of the company’s stock, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 7.60% of the company’s stock.

Institutional Trading of Cardiff Oncology

Several hedge funds have recently added to or reduced their stakes in CRDF. GSA Capital Partners LLP lifted its holdings in shares of Cardiff Oncology by 432.7% in the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after purchasing an additional 151,613 shares in the last quarter. MAI Capital Management raised its position in Cardiff Oncology by 0.7% in the 3rd quarter. MAI Capital Management now owns 663,363 shares of the company’s stock valued at $1,771,000 after buying an additional 4,569 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Cardiff Oncology by 11.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock valued at $324,000 after buying an additional 12,503 shares during the last quarter. State Street Corp lifted its stake in Cardiff Oncology by 3.4% in the 3rd quarter. State Street Corp now owns 832,652 shares of the company’s stock valued at $2,223,000 after acquiring an additional 27,628 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in Cardiff Oncology by 44.3% during the 3rd quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock worth $321,000 after acquiring an additional 36,947 shares during the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.